Previous 10 | Next 10 |
The past two years have been hectic, to say the least, largely due to the COVID-19 pandemic. While we've made some progress on that front, the outbreak is far from over. We are currently experiencing a surge in cases due to the omicron variant of the virus. How will things evolve in 2022? I...
Despite having a billion-dollar drug in its portfolio, the potential for backdoor entry into the marijuana market , and being consistently profitable for years, Jazz Pharmaceuticals (NASDAQ: JAZZ) was battered about the head by the stock market last year with its stock falling 2...
Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader Announces $5 billion revenue target for 2025 Confirms 2021 revenue expected to be within previously announced gu...
Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia Treatment with Xywav resulted in clinically meaningful improvement in idiopathic hypersomnia symptoms, including...
Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd , chairman and chief executive officer, will present vi...
U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults ODE for IH for adults follows June 2021 grant of ODE for treatment of cataplexy or excessive daytime sleepiness i...
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder U.S. FDA granted JZP150 Fast Track designation in PTSD, underscoring the unmet needs of patients If approv...
Jazz Pharmaceuticals (NASDAQ:JAZZ) announces that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety and efficacy of suvecaltamide (also known as JZP385), for the potential treatment of moderate to severe essential tremor (ET), the most common m...
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor PR Newswire DUBLIN , Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nas...
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer The confirmatory trial is designed to secure full approval in the U.S. and serve as ...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...